ArticleSignal transduction and targeted therapy2026

Osimertinib inhibits the MYLK4-mediated phosphorylation of CDKAL1 to suppress stemness and chemoresistance in rhabdomyosarcoma.

Takuto Itano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.